The PTEN/MMAC1 gene at 10q23.3, which has dual specific phosphatase activity, is a novel tumor suppressor gene candidate. Various kinds of tumors have mutations in this gene, including glioblastoma, endometrial carcinoma and prostate cancer. We examined 29 cases of primary non-Hodgkin's lymphoma (NHL) for mutations in the PTEN/MMAC1 gene. One case of diffuse large B cell lymphoma had an 11 bp deletion, but the remaining 28 cases showed no mutations in the genome. Two of these 28 cases showed missense mutations in the PTEN/MMAC1 transcripts, but no alterations in the genomic DNA. These mRNA missense variants are similar to PTEN/MMAC1 transcript aberrations which have been reported in patients with breast cancer. These findings suggest that alterations in the PTEN/MMAC1 gene play a role in the pathogenesis of NHL.
Introduction
Genetic alterations are thought to be critical events in the pathogenesis of malignant lymphoma. Major genetic alterations such as chromosomal translocations are particularly common in NHL, 1, 2 and oncogenes have been found near the breakpoints. [3] [4] [5] Other important genetic events are mutations in tumor suppressor genes (TSGs). Mutations in the p53 6 and p16 7 gene were demonstrated in some patients with lymphoid malignancies, and mutations of p53 were shown to be a significant prognostic factor. 8 Recently, the PTEN/MMAC1 gene at 10q23. 3 , which has been shown to have dual specific phosphatase activity, 9, 10 was identified as a tumor suppressor gene candidate. Mutations of PTEN/MMAC1 gene have been found in various kinds of tumors. Glioblastoma, 11 malignant melanoma 12 and endometrial carcinoma 13 showed a high frequency of PTEN/MMAC1 mutations, but breast carcinoma showed a low frequency of mutation.
14 Cowden disease, which is an inherited disease predisposing carriers to cancer, is thought to be associated with alterations in PTEN/MMAC1 gene. 15 Furthermore, mutations in PTEN/MMAC1 gene, identified in primary tumors, have been demonstrated to result in ablation of phosphatase activity. 16 To our knowledge, there have been no reports of mutations of PTEN/MMAC1 gene in lymphoid malignancy. To determine the extent of the involvement of this gene in lymphoid malignancy, we investigated 29 NHL cases (B cell type, 19 cases; T cell type, 10 cases). A deletion in the genome was found in one case and mRNA missense variants were found in two cases. These data indicate that alterations of PTEN/MMAC1 gene are involved in the pathogenesis of NHL. 
Materials and methods

Tissue samples
Twenty-nine tumor DNA samples were obtained from consenting patients with NHL (diffuse large B cell type, 11 cases; diffuse mixed B cell type, seven cases; diffuse small cleaved B cell type, one case; diffuse mixed T cell type, 10 cases).
Histological diagnosis was performed according to the Working Formulation. Involved lymph nodes and an extranodal lesion (one case from the adrenal cortex) were used as tumor samples in all cases. Peripheral blood mononuclear cells were taken as controls from several patients and a healthy volunteer. Extraction of total RNA and DNA was performed using a previously described technique. 17 
PCR-SSCP
First strand cDNA was synthesized from 1 g of total RNA using random hexamers as primers and MMLV-H reverse transcriptase (Gibco-BRL, Rockville, MD, USA). Mutation screening was performed by RT-PCR-SSCP analysis. 18, 19 For RT-PCR-SSCP, we used four primer sets to cover the entire coding region of the PTEN/MMAC1 gene ( Table 1) . For PCR-SSCP using genomic DNA, the primer sequences were derived from a previous report. 10 PCR amplifications were performed as described previously. 20 Briefly, PCR was carried out for 30 cycles with annealing temperatures at 56°C, with addition of ␣-32 P-dCTP at 1 Ci/reaction. PCR products were separated on 6% neutral polyacrylamide gels (acrylamide/N,N-methylene-bis-acrylamide = 49/1) containing 5% glycerol and 0.5 × MDE gel (FMC BioProducts, Rockland, ME, USA), and exposed to phosphor imaging plates (Imaging plate BASIII; Fuji, Kanagawa, Japan) followed by analysis with a laser image analyzer (FUJIX BAS 2000; Fuji) for visualization.
Direct sequencing
Interest bands at PCR-SSCP analysis were excised from SSCP gels and suspended in 50 1 of distilled water. We used 5 l of each solution as a template for the next amplification with the same set of primers as PCR-SSCP analysis. This amplification was carried out in the same conditions as PCR-SSCP, but the ␣-32 P-dCTP was omitted. These PCR products were separated on 2% low-melting agarose gels and excised, followed by ␤-agarose (New England BioLab, Beverly, MA, USA) treatment. Fifty nanograms of each product was subjected to cycle sequencing (PE Applied Biosystems, Warrington, UK) and analyzed by ABI 310 (Applied Biosystems, Foster City, CA, USA).
Southern blot analysis
Five micrograms of genomic DNA from each tumor sample was digested with EcoRI, separated on 0.8% agarose gel, and subjected to alkali-transfer to Hybond N+ (Amersham, Buckinghamshire, UK) (UPN 4, 8 and 25 were excluded due to lack of sufficient genomic DNA). A cDNA probe of PTEN/MMAC1 gene was generated by PCR using cDNA of peripheral blood mononuclear cells from a normal volunteer with primer sets 1F to 4R. The cDNA probe of PTEN/MMAC1 was randomly labeled with ␣-32 P-dCTP using the Random Primed DNA Labeling Kit (Boehringer Mannheim, Germany), then used for hybridization at previously described condition. 19 Exposure and analysis was performed using phosphor imaging plates and a laser image analyzer.
Results
Mutational analysis of the PTEN/MMAC1 gene by RT-PCR-SSCP revealed shifted bands in three out of 29 NHL cases (Figures 1 and 2 ). UPN11 (diffuse large B cell type, sample from adrenal cortex) showed shifted bands by RT-PCR-SSCP with primer 1F and 1R (Figure 1a ) and an 11 bp deletion (−8-+3) was identified by sequence analysis of this band (Table   2 ). This mutation was also confirmed by PCR-SSCP and direct sequencing of exon 1 using genomic DNA (Figure 1b) , so this alteration is thought to be caused by deletion in the genome and not by alternative splicing. This deletion included the first ATG. The next ATG triplet which fits Kozak's rule 21 starts at +56, but this frame had a stop codon at codon 7. The next ATG triplet is at +103, and this in-frame deletion resulted in a 34 amino acid deletion including the initial methionine. Both of these possible open reading frames would make aberrant protein products.
UPN9 (diffuse small cleaved B cell type) and 24 (diffuse mixed T cell type) showed shifted bands by RT-PCR-SSCP with primer 2F and 2R (Figure 2 ). Sequence analysis of these bands showed multiple point mutations in a single clone (Table 2) . Both patients had the same point mutations at codon 133 (Val to Ile), 135 (Ile to Ile), 136 (Cys to Tyr), 177 (Tyr to Tyr), and 182 (Leu to Val). UPN24 showed another point mutation at codon 186 (Leu to Val) ( Table 2 ). These multiple mutations were confirmed by another RT-PCR-SSCP and direct sequencing. These mutations are located close to the phosphatase core domain. 9 We examined these mutations by PCR-SSCP using genomic DNA (UPN 9 and 24) with primers which amplified exon 5, 10 but could not find any shifted bands. Bands at the wild-type position of these cases were sequenced and confirmed as the wild-type sequence. This evidence suggests that such transcript alterations may be mRNA missense variants.
14 Southern blot analysis showed neither rearranged bands nor a marked decrease in intensity of each band (data not shown). 
Discussion
Phosphatase has been thought to be a potential tumor suppressor gene candidate. 22 In contrast, some protein kinase have been identified as oncogenes. 23 However, so far no protein phosphatases have been reported as tumor suppressor genes. The PTEN/MMAC1 gene is the first phosphatase to be identified as a tumor suppressor gene candidate, and mutations have frequently been found in various kinds of malignant tumors. [9] [10] [11] [12] [13] [14] Kindred of those with Cowden disease, a rare autosomal dominant hereditary cancer syndrome, show a germ line mutation in this gene. 15 Recent biochemical analysis of PTEN/MMAC1 has revealed that some mutations in the PTEN/MMAC1 gene, identified from primary tumors, result in the ablation of its dual specific phosphatase activity. 16 In this study, one case out of 29 NHL cases showed a deletion in the genome. This deletion generates two possible forms of aberrant protein. One is a small polypeptide lacking the phosphatase domain, and the other is an in-frame deletion of the first 34 amino acids (Table 2 ). Although this alteration will conserve the phosphatase domain, certain point mutations outside the phosphatase domain have been reported to result in the loss of its enzymatic activity. 16 Therefore, such a large in-frame deletion might change the conformation resulting in the loss of phosphatase activity. The state of another allele of PTEN/MMAC1 locus in this case should be determined. The intensity of abnormally shifted band was about one-third of wild-type bands by analysis with a laser image analyzer. Due to small fraction of abnormal clone, we could not demonstrate the loss of heterozygosity near the PTEN/MMAC1 locus in this case. We found mutations in tran-scripts of the PTEN/MMAC1 gene in two other cases. These two cases had common mutations at codons 133, 135, 136, 177 and 182, which are very close to the phosphatase core domain. 9 Codons 133, 135 and 136 are within the phosphatase signature motif. 16 Mutations at codons 133, 136, 182 and 186 were missense, thus enzymatic activity might be altered by these mutations. However, such mutations could not been identified when analyzing genomic DNA from the tumors of these patients. Such transcript mutations have also been reported in breast cancer as mRNA missense variants. 14 The origin of mRNA missense variants is unknown, but as mentioned above, these alterations may affect enzymatic activity, and may be involved in the pathogenesis of lymphoma. One possible mechanism to explain how such variants are generated is that a very small fraction of genomic DNA might have mutations which are then overexpressed. Further characterization of mRNA missense variants is necessary to clarify this. Some tumors have homozygous deletions of the PTEN/MMAC1 gene, 9,10 but our Southern blot analysis indicated no homozygous deletion in the samples analyzed. Due to the rarity of mutation, no significant correlations in disease status have been found.
Taken together, our analysis suggests that somatic mutations of the PTEN/MMAC1 gene play a role in the pathogenesis of NHL with a low incidence, and that mRNA missense variants may also be involved in the pathogenesis of NHL.
